Journal article
Adjuvant and Neoadjuvant Small Molecule Targeted Therapy
Abstract
BACKGROUND: Non-localized renal cell carcinoma (rcc) carries a poor prognosis with a significant risk of mortality for patients. Traditionally, interleukin-2 and interferon alfa have been administered in this setting, with high toxicity and limited improvement in cancer-specific survival. However, newer agents such as sunitinib, sorafenib, bevacizumab, and temsirolimus have demonstrated great potential and provide a new frontier in the …
Authors
Kapoor A; Gharajeh A; Sheikh A; Pinthus J
Journal
Current Oncology, Vol. 16, No. 0, pp. 60–66
Publisher
MDPI
Publication Date
May 2009
DOI
10.3747/co.v16i0.415
ISSN
1198-0052